Jeffrey Stuart Peters - 06 Mar 2024 Form 4 Insider Report for MACROGENICS INC (MGNX)

Signature
/s/ Lynn M. Cilinski, Attorney-in-fact
Issuer symbol
MGNX
Transactions as of
06 Mar 2024
Net transactions value
-$421,938
Form type
4
Filing time
08 Mar 2024, 16:14:52 UTC
Previous filing
28 Feb 2024
Next filing
08 Apr 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MGNX Common Stock Options Exercise $125,062 +10,875 +122% $11.50 19,770 06 Mar 2024 Direct
transaction MGNX Common Stock Options Exercise $88,812 +8,750 +44% $10.15 28,520 06 Mar 2024 Direct
transaction MGNX Common Stock Sale $421,938 -19,625 -69% $21.50 8,895 06 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MGNX Employee stock option (right to buy) Options Exercise $125,062 -10,875 -100% $11.50 0 06 Mar 2024 Common Stock 10,875 $11.50 Direct F2
transaction MGNX Employee stock option (right to buy) Options Exercise $88,812 -8,750 -18% $10.15 39,375 06 Mar 2024 Common Stock 8,750 $10.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/10/2022.
F2 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter.